星宇控股(02346.HK)延長增發1億股完成日期
格隆匯7月12日丨星宇控股(02346.HK)公佈,於2020年6月10日,公司與該等認購人訂立該等認購協議,公司擬按每股認購股份0.295港元認購價配發認購股份(即1億股新股份)。認購價0.295港元相當於2020年6月10日公司收市價每股0.365港元折讓約19.18%。
由於需要更多時間以達成該等認購協議所載的先決條件,故公司及各認購人已於2020年7月10日訂立該等認購協議的補充協議,據此,訂約方同意將最後完成日期由2020年7月10日延長至2020年8月10日,或由公司及各認購人可能共同協定的其他日期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.